Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide Maintenance Therapy Post-ASCT in Multiple Myeloma
NCT05177536Phase 2Active, not recruiting
- Sponsor
- University of Nebraska
- Start
- Jun 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by University of Nebraska. Primary endpoint: Proportion of Participants Able to Complete a Minimum of One Year of Therapy at 1 year. Started Jun 2022; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05177536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177536.